This is an open label, two period (fasted and fed), crossover study in up to 3 cohorts of 12 healthy adult participants per cohort (up to 36 participants in total). The pharmacokinetics (PK) of the inactive prodrug VNRX-7145, its active parent drug VNRX-5236, and ceftibuten will be evaluated after a single oral dose of ceftibuten/VNRX-7145.

Inclusion Criteria:

• Healthy adults 18-65 years
• Males or non-pregnant, non-lactating females
• Body mass index (BMI): ≥18.5 kg/m2 and ≤32.0 kg/m2
• Laboratory values meeting defined entry criteria

Exclusion Criteria:

• History of drug allergy or hypersensitivity to penicillin, cephalosporin, or β-lactam antibacterial drug
• Conditions that potentially alter absorption and/or excretion of orally administered drugs
• Congenital or acquired immunodeficiency syndrome
• Positive alcohol, drug, or tobacco use/test